The global diabetic gastroparesis treatment market attained a value of about USD 4 billion in 2020. The market is expected to grow at a CAGR of 4% in the forecast period of 2023-2028.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The market for diabetic gastroparesis treatment is being driven by the improvements in the arena of healthcare and gastric treatments. The market is further aided by the growing cases of diabetes across the globe. Further, the existence of a seamless healthcare industry lays emphasis on the swift treatment and diagnosis, which is also propelling the market forward. Diabetic gastroparesis severely affects the quality of life. Therefore, medical practitioners are showing tremendous concern for the patient while treating such disorders, consequently enhancing the market growth. In addition, the availability of dieticians and professionals who can advise the patient regarding proper food consumption and food habits is also contributing to the market growth of diabetic gastroparesis treatment. All these factors are expected to support the market growth over the forecast period as well.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Diabetic gastroparesis treatment is the treatment for delayed gastric emptying related to diabetes. The condition is observed in patients suffering from type-1 and type-2 diabetes and is found to be frequent in female patients that are suffering from type-2 diabetes.
On the basis of type, the market is divided into:
Based on disease indication, the industry can be segmented into:
By distribution channel, the industry is categorised into:
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The diabetic gastroparesis treatment industry is being driven by the need to meet the evolving demands within the diabetic treatment and diagnostics sector. The market is further aided by the rising cases of type-I and type-II diabetes. Furthermore, the rising demand for minimally invasive treatments and surgeries for the diabetic gastroparesis is also providing an impetus to the market growth as it has created significant growth opportunities within the industry. Moreover, the development of new drug lines within the industry is expected to boost the market growth of diabetic gastroparesis treatment over the forecast period.
The report gives a detailed analysis of the following key players in the global diabetic gastroparesis treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Type||
|Breakup by Disease Indication||
|Breakup by End User||
|Breakup by Route of Administration||
|Breakup by Region||
|Report Price and Purchase Option||Explore our purchase options that are best suited to your resources and industry needs.|
|Delivery Format||Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Diabetic Gastroparesis Overview
3.1 Guidelines and Stages
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Diabetic Gastroparesis Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Diabetic Gastroparesis Epidemiology (2016-2031)
5.3 Europe Diabetic Gastroparesis Epidemiology (2016-2031)
5.4 Asia-Pacific Diabetic Gastroparesis Epidemiology (2016-2031)
5.5 Latin America Diabetic Gastroparesis Epidemiology (2016-2031)
5.6 Middle East & Africa Diabetic Gastroparesis Epidemiology (2016-2031)
6 Diabetic Gastroparesis Treatment Market Overview
6.1 Diabetic Gastroparesis Treatment Market Historical Value (2016-2022)
6.2 Diabetic Gastroparesis Treatment Market Forecast Value (2023-2031)
7 Diabetic Gastroparesis Treatment Market Landscape
7.1 Diabetic Gastroparesis Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Diabetic Gastroparesis Treatment Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by End User
8 Diabetic Gastroparesis Treatment Market Dynamics
8.1 Market Drivers and Constraints
8.2 SWOT Analysis
8.3 Porter’s Five Forces Model
8.4 Key Demand Indicators
8.5 Key Price Indicators
8.6 Industry Events, Initiatives, and Trends
8.7 Value Chain Analysis
9 Diabetic Gastroparesis Treatment Market Segmentation
9.1 Diabetic Gastroparesis Treatment Market by Type
9.1.1 Market Overview
9.1.2 Surgical Treatment Products
9.2 Diabetic Gastroparesis Treatment Market by Disease Indication
9.2.1 Market Overview
9.2.2 Compensated Gastroparesis
9.2.3 Gastric Failure
9.3 Global Gastroparesis Treatment Market by End User
9.3.1 Market Overview
9.3.3 Specialty Clinics
9.4 Global Gastroparesis Treatment Market by Route of Administration
9.4.1 Market Overview
9.5 Diabetic Gastroparesis Treatment Market by Region
9.5.1 Market Overview
9.5.2 North America
9.5.4 Asia Pacific
9.5.5 Latin America
9.5.6 Middle East and Africa
10 North America Diabetic Gastroparesis Treatment
10.1 Market Share by Country
10.2 United States of America
11 Europe Diabetic Gastroparesis Treatment
11.1 Market Share by Country
11.2 United Kingdom
12 Asia Pacific Diabetic Gastroparesis Treatment
12.1 Market Share by Country
13 Latin America Diabetic Gastroparesis Treatment
13.1 Market Share by Country
14 Middle East and Africa Diabetic Gastroparesis Treatment
14.1 Market Share by Country
14.2 Saudi Arabia
14.3 United Arab Emirates
14.5 South Africa
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 INDIA CDSCO
15.1.4 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Evoke Pharma Inc.
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.2 Allergen Pnc.
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.3 Salix Pharmaceuticals
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.4 Theravance Biopharma Inc.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.5 Medtronics pLC
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.7 Rhythm Pharmaceuticals
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.8 Allergen plc.
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.9 Astrazeneca plc.
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.10 Cadila Pharmaceuticals
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.11 Neurogastrx Inc
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.12 Bausch Health
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
22 Diabetic Gastroparesis Treatment - Distribution Model (Additional Insight)
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
In 2020, the global diabetic gastroparesis treatment market attained a value of nearly USD 4 billion.
The market is projected to grow at a CAGR of 4% between 2021 and 2026.
The major drivers of the industry, such as rising disposable incomes, increasing population, growing improvements in the arena of healthcare and gastric treatments, rising prevalence of diabetes, increasing availability of dieticians and professionals, and growing demand for minimally invasive treatments and surgeries for the diabetic gastroparesis, are expected to aid the market growth.
The key trends guiding the growth of the market include the rising development of new drugs and advancements in the healthcare industry.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The leading types of diabetic gastroparesis treatment in the industry are surgical treatment products and drugs.
The major disease indications in the market are compensated gastroparesis and gastric failure, among others.
The significant distribution channels in the industry are hospital pharmacies, drug stores, private clinics, and retail pharmacies, among others.
The major players in the industry are Evoke Pharma, Inc., Allergan plc, Salix Pharmaceuticals, Theravance Biopharma, Inc., and Medtronic, plc, among others.
The global diabetic gastroparesis treatment market attained a value of USD 4 billion in 2020, driven by the rising occurrence of diabetes. Aided by the advancements in the healthcare infrastructure, the market is expected to witness a moderate growth in the forecast period of 2023-2028, growing at a CAGR of 4%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on type, the market is segmented into surgical treatment products and drugs. On the basis of disease indication, the industry is divided into compensated gastroparesis and gastric failure, among others. The major distribution channels in the market are hospital pharmacies, drug stores, private clinics, and retail pharmacies, among others. The major regional markets for diabetic gastroparesis treatment are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Evoke Pharma, Inc., Allergan plc, Salix Pharmaceuticals, Theravance Biopharma, Inc., and Medtronic, plc, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Single User License
Five User License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.